NCT05465343 is a Phase 2 clinical trial of Furmonertinib 160 mg, Q.D. in Furmonertinib, sponsored by Peking Union Medical College.

Who is sponsoring NCT05465343?

NCT05465343 is sponsored by Peking Union Medical College.

What drugs are being tested in NCT05465343?

Interventions in NCT05465343: Furmonertinib 160 mg, Q.D..

What condition does NCT05465343 study?

NCT05465343 studies Furmonertinib, EGFR-mutation, NSCLC, Brain Metastases.

Is NCT05465343 still recruiting?

NCT05465343 is currently completed. Last updated 19 December 2025.

Last reviewed 2025-12-19 · How we verify

NCT05465343

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)

Completed Phase 2 Last updated 19 December 2025

What this trial tests

Phase 2 trial testing Furmonertinib 160 mg, Q.D. in Furmonertinib in 24 participants. Completed in 12 December 2025.

Timeline

11 July 2022

Primary endpoint
12 December 2025

12 December 2025

Quick facts

Lead sponsor	Peking Union Medical College
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	11 July 2022
Primary completion	12 December 2025
Estimated completion	12 December 2025
Sites	1 location across China

Drugs / interventions tested

Furmonertinib 160 mg, Q.D. — full drug profile →

Conditions studied

Furmonertinib — all drugs for Furmonertinib →
EGFR-mutation — all drugs for EGFR-mutation →
NSCLC — all drugs for NSCLC →
Brain Metastases — all drugs for Brain Metastases →

Sponsor

Peking Union Medical College

Who can join

18 and older, any sex, with Furmonertinib or EGFR-mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single-arm, open-label, prospective phase II trial. The aim of this phase II study is to evaluate the efficacy and safety of Furmonertinib in patients with EGFR mutation (including 19del or 21L858R or T790M) in advanced NSCLC with brain metastases.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, "uncommon-G719X, S768I, L861Q") Among the Third-Generation EGFR TKIs?
Zhang SS, Ou SI. · · 2022 · cited 22× · PMID 36317157 · DOI 10.2147/lctt.s385437
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies.
Hu X, Zhang S, Ma Z, Feng J, et al · · 2023 · cited 16× · PMID 37118803 · DOI 10.1186/s12916-023-02865-z
Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy.
Xu Z, Hao X, Wang Q, Yang K, et al · · 2023 · cited 16× · PMID 36870951 · DOI 10.1186/s12885-023-10676-x
First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review.
Han H, Zhang X, Liu X, Zhao J, et al · · 2023 · cited 6× · PMID 38206746 · DOI 10.1097/md.0000000000036667
The current landscape, advancements, and prospects in the treatment of patients with EGFR exon 20 insertion mutations warrant scientific elucidation.
Man X, Sun X, Chen C, Xiang Y, et al · · 2024 · cited 2× · PMID 38919530 · DOI 10.3389/fonc.2024.1367204

Verify or expand the search:

Other trials of Furmonertinib 160 mg, Q.D.

Trials testing the same drug.

NCT05548348 — First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation · Phase 2 · unknown

Other recruiting trials for Furmonertinib

Currently open trials in the same condition.

NCT07348965 — Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis · NA · recruiting

Other Peking Union Medical College trials

Trials by the same sponsor.

NCT05917418 — Nutritional Support on Outcomes and Cost-effectiveness for Patients at Risk · NA · not yet recruiting
NCT07261072 — Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS · Phase 4 · not yet recruiting
NCT06026709 — Effectiveness and Cost-effectiveness of Digital Psychological Intervention (EmoEase) in Chinese COPD Patients · NA · not yet recruiting
NCT07183033 — Exploratory Trial of VR Intervention on Neuroplasticity in Older Adults With Cognitive Frailty · NA · enrolling by invitation
NCT07109765 — Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05465343 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College
Last refreshed: 19 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05465343.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing